- Raw materials
- Antibacterials
- Penimepicycline
Penimepicycline API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Penimepicycline | CAS No: 4599-60-4 | GMP-certified suppliers
A medication that serves as a systemic antibacterial agent within the tetracycline class, intended for use in anti-infective therapies targeting bacterial infections.
Therapeutic categories
Product Snapshot
- Penimepicycline is an oral small molecule antibiotic formulation
- It is primarily developed for antibacterial therapeutic applications
- The compound is currently in experimental status and has not received FDA or EMA approval
Clinical Overview
The compound is listed on the Government of Canada List A, which catalogs antimicrobial active pharmaceutical ingredients of clinical relevance. Within this classification, tetracycline antibiotics, including penimepicycline, are considered to hold medium importance for human therapeutic applications. However, penimepicycline itself remains in an experimental category, with no specific clinical indications or approved therapeutic uses described at this time.
Pharmacodynamic data and mechanistic details specific to penimepicycline are not documented in the available sources. Given its structural classification, it is inferred to share the general mode of action common to tetracyclines, which typically involves the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit, thereby preventing aminoacyl-tRNA attachment. Nonetheless, confirmation of this mechanism in penimepicycline requires further research.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for penimepicycline have not been established. Safety and toxicity profiles remain uncharacterized due to its experimental status, and no specific safety warnings or adverse effect data are currently available. Likewise, there are no noted commercial brand names or widely recognized usage contexts at present.
For pharmaceutical formulation scientists and API sourcing professionals, penimepicycline's inclusion on regulatory lists such as the Canadian List A underscores the need for quality assurance in sourcing. Procurement of the API should focus on obtaining material that complies with relevant purity standards and manufacturing controls consistent with antimicrobial active pharmaceutical ingredient guidelines, ensuring identity, potency, and absence of contaminants, especially given the lack of extensive clinical data.
Identification & chemistry
| Generic name | Penimepicycline |
|---|---|
| Molecule type | Small molecule |
| CAS | 4599-60-4 |
| UNII | 3RGQ4B6E87 |
| DrugBank ID | DB13264 |
Formulation & handling
- Penimepicycline is a small molecule tetracycline derivative primarily formulated for oral administration due to its chemical class and solubility profile.
- The compound exhibits high water solubility and low logP, indicating good aqueous dissolution but potentially limited membrane permeability.
- Stability considerations should include protection from light and avoidance of divalent cations to prevent chelation and loss of activity typical of tetracyclines.
Regulatory status
Penimepicycline is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
